Group items tagged

Research shows that many doctors rely more on the pharmaceutical industry's own information about a medication than on checking independent sources for evaluations of the drug.

Search this online database for comprehensive information on FDA-approved pharmaceutical drugs.

medical professionals healthcare hospitals schools labs database search dB doctors healthcare opinion-leaders key opinion leaders social-network-analysis SNA people pharma pharmaceutical marketing decision-makers decisionmakers influence

Amgen to Zeneca!

There is no simple way to preserve the entrepreneurial spirit that has created MRI scans, stents, bioengineered drugs, and artificial knees - and completely eliminate financial conflicts of interest...Even with rigorous guidelines, pharmaceutical companie

Rhabdomyolysis is more frequent than reported in medical journals, by pharmaceutical companies, and other standard avenues of information on adverse side effects in drugs. Polyneuropathy is an increased risk in diabetics... [I must FIND STUDIES, ETC. to support this blogpost]

The Scientist published that "Merck paid an undisclosed sum to Elsevier to produce several volumes of a publication that had the look of a peer-reviewed medical journal, but contained only reprinted or summarized articles--most of which presented data favorable to Merck products--that appeared to act solely as marketing tools with no disclosure of company sponsorship. "

The fact that an increasing number of medications are unable to beat sugar pills has thrown the industry into crisis. It's not that the old meds are getting weaker, drug developers say. It's as if the placebo effect is somehow getting stronger. Why are inert pills suddenly overwhelming promising new drugs and established medicines alike? Pharma doesn't know, and drugmakers are realizing they need to fully understand the mechanisms behind it so they can design trials that differentiate more clearly between the beneficial effects of their products and the body's innate ability to heal itself. special task force of the Foundation for the National Institutes of Health is seeking to stem the crisis by quietly undertaking one of the most ambitious data-sharing efforts in the history of the drug industry.